The U.S. Food and Drug Administration approved DexCom, Inc.’s (NASDAQ:DXCM) Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes. With an overall Mean Absolute ...

The Food and Drug Administration has cleared diabetes-management firm DexCom's new continuous glucose monitoring (CGM) system ...

Stock futures dipped on Thursday as investors weighed President Trump’s 90-day tariff reprieve for select countries, which ...

What should investors do during a market downturn? Some might resort to panic selling, but that's hardly a good strategy.

Notable gainers among liquid option names this morning include DexCom (DXCM) $71.65 +4.81, Consolidated Edison (ED) $108.50 +2.73, SBA ...

DexCom (DXCM) announced the FDA has cleared the Dexcom G7 15 Day continuous glucose monitoring system for people over the age of 18 with ...

Dexcom (Nadsaq:DXCM) announced today that the FDA cleared its G7 15-day continuous glucose monitoring (CGM) system.

The San Diego-based medical device company stated that the Dexcom G7 15 Day has an overall Mean Absolute Relative Difference (MARD) of 8.0%, showcasing its precision in glucose level readings. The ...

DexCom, Inc. , the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes in the ...

Fintel reports that on April 10, 2025, Mizuho initiated coverage of DexCom (NasdaqGS:DXCM) with a Outperform recommendation. Analyst Price Forecast Suggests 57.82% Upside As of April 1, 2025, the ...

DexCom DXCM underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing ...

DexCom Inc. closed 52.68% below its 52-week high of $141.25, which the company reached on April 11th.